The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Unfortunately, all successful pharma's need to be States centric to the extent that FAD approval and progress through the clinical trials with them on board is absolutely essential. The USA is the biggest drug market in the world for sophisticated and topical drugs.
The fact that VRP has gained a NASDAQ listing and held it for some time tells you that the efficacy of the compound is probably known.
Nobody can be in any doubt that the FDA has been distracted of late otherwise VRP would be much further forward in the process than they are.
As I've said before, if the news about the trials of the VRP drug against COvid 19 had broken when the shares were pennies then we would have had a stampede of PI's ploughing in trebling the price overnight. Luckily because VRP is no longer a penny share the current share price hasn't been pumped and hardly reflects the true intrinsic value of the business and remains a stand out opportunity to buy and would be if the share price was 3 x what it is today.
AIMHO and DYOR
we have about $200m in cash, and company value is much lower than sng, considering our cash.
SNG has very good potential in drug application and effectiveness of curing the covid, but they do have the possibility of placing to fund themselves further for trial III
we are trail III on copd.
FDA recommendation on cov19
totally agree bewis.
I feel this will be next sng, I am not saying it will jump on sp 400% a day, I am saying the potential of effectiveness of curing cov19 from copd drug. A potential world changer stock! and much better funded than sng. I was in from the FDA news and topped up twice ever since. Will just hold for a few months to lease out the potential...
i don't understand why people selling now at 85p, as you could sell 20k no problem, but need to go NT for 200 shares.
media coverage all over the weekend and further on.
good luck all holders.
The market is realizing the value ensifentrine and this cheap sp. We should storm past a £ imo and back to the level we should of always been at £1.50 +. The funding issue has now been sorted so a clear road ahead. The world needs ensifentrine in this dreadful pandemic...
Imo they are States centric, a larger and more lucrative market $$$ but no doubt in the fullness of time the NHS will benefit along with the rest of the world. $£€ :)
Zzzzz
Very difficult to buy had to pay top money!!!!
Everybody sounds confident that this is exactly what the covid patients need,why not offer it to patients over here and see them benefit,the NHS benefit and get the show on the road.
Thanks Buddy, yes I can see the Times article on the net. If ensifentrine proves successful against the after effects of Covid 19 a rocket will be placed under this share price. This will be big news!
Also fairly reasonable size article in the Times business page 47.
All publicity is good and yes as you rightly say finished 14 pc up in the states.
All- have a good weekend.
Some press coverage in the Daily Mail today re Verona's Covid19 announcement, just need some BBC coverage now :)
Not a bad finish in the states..imo don't get to bothered about the weekly or monthly share price movement, we are closer to the end now and if successful in P3 and with other strings to our bow now we have a valuable and desirable asset. :)
The very reason why I will not invest until it hits £2 as previously stated as then will be sufficiently derisked to be feel confident about. It should really be £2 now except inmo for the massive opportunities they have missed and poor decision making previously. The new management are tarred with the same brush as the previous incumbents due to their ridiculous pay and option awards. This dropped 10% the other day so in effectback to square one with a covid announcement 6 mths to late....DUH DUH DUH.
Did anyone listen?
It all seems to be going downhill now!
Can’t really understand why although very typical of the share!
An RNS such as this and it rises 13 pc!
Could be back to 72 p by the close.
Is it something they said on the newscast? Lol!
Cheers Rhodi, appreciate it but as you know a long way to go
Hope your keeping well
We shall see!
At Mid day the pre market prediction was 30 pc.
At present it’s gone down to 15.
However I do hope you are right!
The States will drive the sp...gla
Great news for Covid 19 sufferers, great news for investors...good times ahead guys :)
Enjoy the ride. Not before time investors have been calling for it to be used pre or post for covid sufferers and 6mths on they make the announcement . The dual action had always made this an excellent match as it is the inflammation that worsens the C19 condition to eventually lead to pneumonia which ensifenterine would massively combat against plus the dilatory effect would help the flow of oxygen. I was a staunch advocate of this much to the bemusement of a couple of posters. Well this could be a very nice extra. This along with the speed up in the 2nd trials for is it Mdi or dpi bodes very well as that could see a partnership. I have all my money tide in other worthy investments but wish you all well. Once institutions realise that they are actually persuing Covid as a further diseaase that ensifenterine can treat in a blockbuster copd multi dimensional play that includes COPD, asthma and Cystic fibrosis then this may get to lead the charts today. Once Nasdaq kicks in and this gets out more in the press I would not be surprised to see over a 75% increase and with news due in the 2nd half and early next year and possible partnership of MDi and Dpi which the chines have always been interested in then this might be on a very upwardly mobile curve. Pity that imo they have been way to slow to act but hopefully they have been doing some very good work in the background under the new leadership which will be a first. Finally Izstar and Digger and bewise and others your time has come. Happy with my current investments and good luck to you but feel very positive for you all. Has been a long time in the making
Yes, if the USA like today’s RNS, which I expect they will, then any movement “should” be reflected here. Remember that there are 8 Aim shares to every Nasdaq ADS plus the exchange rate difference.
Come on Bewise fess up to being high up in VRP, I have said so before and your post on Monday endorses that view. Your knowledge over the years has been far more than the average lay investor.
@Bewise - Monday 2126
If this ever makes it to market, I wonder whether 'other respiratory diseases' also includes the fall-out from Covid-19. We see scarring in the lungs of patients who have been seriously unwell because of C-19, this possibly also has a similar presentation to COPD. Meaning this could be a line of treatment to help survivors of C-19.
True, but im happy that it is stable which gives a better launch pad for the next big rise when it comes. We might get a reasonable start tomorrow with that late buy of 40k shares.
Been fiddling around all day today!
A bloody pain!!